2020
Prognostic and Predictive Biomarkers in Oligometastatic Disease.
Barnum KJ, Weiss SA. Prognostic and Predictive Biomarkers in Oligometastatic Disease. The Cancer Journal 2020, 26: 100-107. PMID: 32205533, PMCID: PMC9208067, DOI: 10.1097/ppo.0000000000000438.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCirculating Tumor DNAClinical Decision-MakingDisease-Free SurvivalHumansMicroRNAsMutationNeoplasmsNeoplastic Cells, CirculatingPatient SelectionPrognosisProgression-Free SurvivalRadiofrequency AblationRadiosurgeryRisk AssessmentSurvival RateConceptsLocal therapyOligometastatic diseaseSystemic therapyPredictive biomarkersCurative-intent local therapyAdvanced disease stateCancer-related deathSurvival benefitPatient candidatesMetastatic lesionsPatient selectionPoor prognosisAblative treatmentClinical definitionTumor biologyTherapyOligometastasesDisease statesDiseasePatientsLocal interventionsBiomarkersPolymetastasesPrognosisLesions
2019
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
Klemen ND, Wang M, Feingold PL, Cooper K, Pavri SN, Han D, Detterbeck FC, Boffa DJ, Khan SA, Olino K, Clune J, Ariyan S, Salem RR, Weiss SA, Kluger HM, Sznol M, Cha C. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. Journal For ImmunoTherapy Of Cancer 2019, 7: 196. PMID: 31340861, PMCID: PMC6657062, DOI: 10.1186/s40425-019-0672-3.Peer-Reviewed Original ResearchConceptsThree-year progression-free survivalProgression-free survivalDisease-specific survivalFive-year disease-specific survivalPatterns of failureDurable progression-free survivalLocal therapyStereotactic body radiotherapyMetastatic melanomaNew metastasesPatient selectionIndependent radiological reviewOngoing complete responseResultsFour hundred twentyEvidence of diseaseCNS metastasisCPI treatmentImmunotherapy failureCheckpoint inhibitorsMost patientsProgressive diseaseRadiological reviewComplete responsePD-1PD-L1
2015
Revisiting determinants of prognosis in cutaneous melanoma
Weiss SA, Hanniford D, Hernando E, Osman I. Revisiting determinants of prognosis in cutaneous melanoma. Cancer 2015, 121: 4108-4123. PMID: 26308244, PMCID: PMC4666819, DOI: 10.1002/cncr.29634.Peer-Reviewed Original ResearchConceptsDeterminants of prognosisCutaneous melanomaStaging systemCurrent staging modelsCurrent staging systemLymph node spreadPrimary tumor thicknessAmerican Joint CommitteeCancer (AJCC) staging systemPresence of ulcerationPrimary cutaneous melanomaUseful prognostic biomarkerMelanoma staging systemNew prognostic toolClinical surveillance strategiesAdjuvant therapyAdvanced diseaseDistant metastasisPatient selectionNode spreadSurvival outcomesTumor thicknessImmunologic markersPatient prognosisPatient outcomes